Table 3.
Multivariable model examining factors associated with prescription fills for abiraterone or enzalutamide by specialty
| Medical Oncology | Urology | |||
|---|---|---|---|---|
| Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value | |
| Payment | ||||
| $0 | Ref | <0.01 | Ref | 0.01 |
| $1–$999 | 1.69 (1.59–1.79) | 4.04 (3.59–4.54) | ||
| ≥$1000 | 2.61 (2.14–3.18) | 13.57 (9.69–19.0) | ||
| Year of payment | ||||
| 2014 | Ref | <0.01 | Ref | <0.01 |
| 2015 | 1.14 (1.10–1.19) | 1.79 (1.59–2.03) | ||
| 2016 | 1.15 (1.10–1.21) | 2.18 (1.91–2.50) | ||
| 2017 | 1.17 (1.10–1.23) | 2.14 (1.85–2.47) | ||
| Age | 1.00 (1.00–1.00) | 0.81 | 1.00 (1.00–1.01) | 0.10 |
| Gender | ||||
| Male | Ref | <0.01 | Ref | <0.01 |
| Female | 0.48 (0.44–0.51) | 0.14 (0.08–0.27) | ||
| Region | ||||
| South | Ref | <0.01 | Ref | 0.09 |
| Northeast | 0.73 (0.66–0.79) | 0.95 (0.79–1.13) | ||
| Midwest | 1.03 (0.94–1.12) | 1.18 (0.99–1.41) | ||
| West | 1.18 (1.08–1.28) | 0.90 (0.75–1.09) | ||
Abbreviations: CI, confidence interval; Ref, reference.
Results shown are odds radios with 95% confidence intervals of prescribing abiraterone or enzalutamide relative to not prescribing either drug.